Mammalian l-to-d-amino-acid-residue isomerase from platypus venom  by Torres, Allan M. et al.
FEBS Letters 580 (2006) 1587–1591Mammalian L-to-D-amino-acid-residue isomerase from platypus venom
Allan M. Torresa, Maria Tsampazia, Chryssanthi Tsampazia, Eleanor C. Kennetta,
Katherine Belovb, Dominic P. Geraghtyc, Paramjit S. Bansald, Paul F. Alewoodd,
Philip W. Kuchela,*
a School of Molecular and Microbial Biosciences, University of Sydney, Building G08, Sydney, NSW 2006, Australia
b Faculty of Veterinary Science, University of Sydney, Camden, NSW 2570, Australia
c School of Human Life Sciences, University of Tasmania, Launceston, Tasmania 7250, Australia
d Institute for Molecular Bioscience, University of Queensland, Brisbane, Qld 4072, Australia
Received 7 December 2005; revised 20 January 2006; accepted 24 January 2006
Available online 3 February 2006
Edited by Maurice MontalAbstract The presence of D-amino-acid-containing polypep-
tides, defensin-like peptide (DLP)-2 and Ornithorhyncus venom
C-type natriuretic peptide (OvCNP)b, in platypus venom sug-
gested the existence of a mammalian D-amino-acid-residue isom-
erase(s) responsible for the modiﬁcation of the all-L-amino acid
precursors. We show here that this enzyme(s) is present in the ve-
nom gland extract and is responsible for the creation of DLP-2
from DLP-4 and OvCNPb from OvCNPa. The isomerisation
reaction is freely reversible and under well deﬁned laboratory
conditions catalyses the interconversion of the DLPs to full
equilibration. The isomerase is 50–60 kDa and is inhibited by
methanol and the peptidase inhibitor amastatin. This is the ﬁrst
known L-to-D-amino-acid-residue isomerase in a mammal.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The Australian duck-bill platypus, Ornithorhynchus anati-
nus, is unique among mammals as the adult male has pelvic ve-
nom (crural) glands, and a venomous spur on each hind limb
[1]. The venomous spurs are used as oﬀensive and defensive
weapons and the toxins cause excruciating pain to victims
[2]. Platypus venom contains many non-protein and protein
components (see Fig. 1) whose roles are yet to be established.
Among these is a group of four polypeptides of 5 kDa re-
ferred to as defensin-like peptides (DLPs) [3–5], whose tertiary
structures resemble that of b-defensins, but they have not thus
far shown anti-microbial properties. Natriuretic peptides,
Ornithorhyncus venom C-type natriuretic peptide (OvCNPa
and OvCNPb), are better understood, as in rats they cause
smooth muscle relaxation and mast cell histamine release.
The natriuretic peptides are the most physiologically active
components discovered in the venom to date [6–10].
We previously discovered that OvCNPb and DLP-2 each
contain a D-amino acid residue at position 2, while their coun-Abbreviations: DLP, defensin-like peptide; MW, molecular weight;
OvCNP, Ornithorhyncus venom C-type natriuretic peptide; RP-HPLC,
reverse-phase HPLC
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doi:10.1016/j.febslet.2006.01.089terparts OvCNPa and DLP-4 have all L-forms [11,12]. The
occurrence of biologically active D-amino-acid-containing-
peptides in higher organisms is rare but has been reported in
frogs [13–15], molluscs [16–19], spiders [20,21], and crustaceans
[22–24]. D-amino-acid-containing peptides are more stable in
tissues as they are less susceptible to protease degradation.
Some of these unusual peptides are more potent than the reg-
ular all L-forms of the peptides [15,16,20]. They most certainly
are created post-translationally from regular peptides via a
special enzyme referred to as peptidylaminoacyl-L/-D-isomer-
ase [25,26] or simply, here, isomerase.
In our recent paper on DLP structure, we showed that the
platypus venom gland extract has isomerase activity that con-
verts DLP-4 to DLP-2 [12]. Therefore, we set out to character-
ize the enzyme responsible for this activity and to ultimately
determine whether orthologous isomerases and hence D-ami-
no-acid-containing peptides are found in other mammals,
including humans. In this study, we introduce the isomerase
in platypus venom and describe some of its biochemical and
biophysical properties. To investigate the speciﬁcity of this en-
zyme, two 12-residue peptide analogues that incorporate the
ﬁrst seven residues of DLP-2 and DLP-4 were chemically syn-
thesized and tested for interconversion. We also show that the
platypus venom gland extract contains isomerase activity that
interconverts OvCNPa and OvCNPb, suggesting a possible
broad-range substrate-speciﬁcity isomerase that acts on both
DLPs and OvCNPs.2. Materials and methods
2.1. Preparation of venom-gland extracts, DLP, OvCNP, and DLP
analogue samples
The venom glands used were obtained from adult male platypuses in
Tasmania, that had been killed accidentally on roads. Details of the
preparation of the venom-gland extract are described in Torres et al.
[12]. Native DLP-2, DLP-4, OvCNPa and OvCNPb were isolated from
the venom gland extracts by reverse-phase HPLC (RP-HPLC). Syn-
thetic versions of these peptides, including the twoDLP analogues, were
produced manually using 2-(1-H-benzotriazol-1-yl-)1,1,3,3 tetrameth-
yluronium hexaﬂuorophosphate activation of Boc-amino acids with
in situ neutralization chemistry, as previously described [11,27].
2.2. Assay of L-to-D-amino-acid-residue isomerase
An Amicon Ultrafree-MC with 30 kDa nominal molecular weight
(MW) cut-oﬀ was used to fractionate the venom-gland extract. The
isomerase-active retentate that contained components with nominal
MW > 30 k was washed twice by reconstituting it with two volumesblished by Elsevier B.V. All rights reserved.
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Fig. 1. RP-HPLC of platypus venom gland extract and primary
structures of peptides acted upon by the isomerase. (A) RP-HPLC of
50 lL platypus venom gland extract. The components were eluted with
a gradient of 20–45% acetonitrile containing 0.1% (v/v) TFA at 1.0 mL
min1, for 40 min. (B) Primary structures of DLP-2/DLP-4, OvCNPa/
OvCNPb, and synthetic DLP-2A/DLP-4A. The second amino-acid
residues shown in bold are in the L-form in DLP-4, OvCNPa, and
DLP-4A but are in the D-form in DLP-2, OvCNPb, DLP-2A. The
disulﬁde-bonding patterns are shown by lines below the sequences.
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saline, PBS) at pH 7.4 and repeating the ﬁltration. Finally, the reten-
tate was reconstituted to the original volume with 50 mM PBS.
A typical incubation mixture consisted of 20 lL of fractionated ve-
nom gland extract, 20 lL of 50 mM PBS, 10 lL of peptide (0.3 mM)
and 6 lL of 40 mM EDTA. This mixture was incubated either at 32 C
(the average body temperature of the platypus) or 37 C in a water
bath, for 24 h and sampled at speciﬁed times to monitor the conver-
sion to the other form by RP-HPLC.
2.3. Chromatography
A Phenomenex Synergi 4 l Hydro-RP analytical column
(250 mm · 4.60 mm) was used in RP-HPLC. The solvent system con-
sisted of 0.1% (v/v) triﬂuoroacetic acid in water (Buﬀer A) and 0.1%
(v/v) triﬂuoroacetic acid in acetonitrile (Buﬀer B). Samples with vol-
umes ranging from 5 to 200 lL were applied at a ﬂow rate of 1 mL
min1, and separated components were detected at light wavelengths
of 215 or 280 nm. The elution gradients for DLP, OvCNP, and DLP
analogues were 28–35% B for 11 min, 25–31% B for 10 min, and 5–
60% B for 15 min, respectively.
Size-exclusion chromatography was performed using a Pharmacia
Superdex 75 HR 10/30 column equilibrated with buﬀer containing
50 mM PBS at pH 7.4. Gland extracts with typical volumes ranging
from 50 to 200 lL were eluted at 500 lL min1 ﬂow rate and were
monitored at light wavelengths of both 215 and 280 nm.3. Results
3.1. Interconversion of DLP-4 and DLP-2
In our previous study [12], the isomerase activity was con-
ﬁrmed when DLP-2 was observed after a 4 h incubation at
33 C of a mixture containing DLP-4 and fractionated gland
extract containing proteins with MW > 30 k. In this study,
we performed the experiment at 37 C (to increase the rateof conversion) and found that the relative peak intensities of
the two DLPs became equalized after 1 h of incubation and
then remained constant (see Fig. 2A), suggesting that the con-
version was reversible and went to full equilibration. The
reversibility of the conversion was tested by using DLP-2 as
a substrate instead of DLP-4. As shown in Fig. 2B, the peak
corresponding to DLP-4 appeared after 1 h and remained rel-
atively constant after 4 h of incubation. This conﬁrmed that
the isomerization process was indeed reversible and that the
enzyme interconverts DLP-2 and DLP-4.
3.2. Interconversion of DLP-2 and DLP-4 analogues
Two 12-residue DLP analogues, DLP-4A and DLP-2A,
were assayed to determine if smaller peptides are acted upon
by enzyme in the fractionated gland extract. These two pep-
tides are identical in their ﬁrst seven residues with DLP-2
and DLP-4, and are followed by Ser-Arg-Ser-Arg-Ser to make
them soluble in aqueous solution. As shown in Figs. 2C and D,
these analogues were converted to the other form in 1 h (at the
same enzyme concentration as used previously) and conversion
reached full equilibration in 3–4 h.
3.3. Interconversion of OvCNPa and OvCNPb
An RP-HPLC peak corresponding to OvCNPb was clearly
seen after 2 h of incubation of fractionated venom gland ex-
tract (MW > 30 k) and OvCNPa (see Fig. 2E), and its intensity
increased up to 24 h. Thus, an active isomerase with an
MW > 30 k converted OvCNPa to OvCNPb in the venom
gland extract. The dramatic decrease in OvCNPa between 2
and 24 h may be attributed to degradation possibly due to pro-
tease activity and/or by other means, such as aggregation, as
we found that OvCNPa by itself was not very stable in solu-
tion. The conversion of OvCNPa to OvCNPb was reversible,
as OvCNPa was formed when OvCNPb was incubated using
a similar >30 kDa gland extract (see Fig. 2F). The conversion
of OvCNPs was much slower than that of the DLPs for a given
amount of extract.
3.4. Inhibition of DLP isomerase with amastatin and methanol
Amastatin has limited solubility in water so it was dissolved
in methanol prior to addition to an incubation mixture con-
taining DLP-2. This meant that methanol would always be
present in samples containing amastatin hence two control
experiments, one with and one without methanol, were re-
quired. Fig. 3 shows RP-HPLC chromatograms of three sam-
ples after 3 h of incubation at 37 C. The sample with 0.23 mM
amastatin and methanol showed complete inhibition, while
partial inhibition was observed for the sample containing
methanol alone.3.5. Size-exclusion chromatography
Figs. 4A and B show the size-exclusion chromatogram and
SDS–PAGE gel of the venom gland extract. Five obvious
bands are evident in the gel (Fig. 4B); a major protein with
molecular size 57 kDa exists with four minor proteins of
4, 67, 80, and 110 kDa. Size-exclusion chromatography
using Superdex 75 detected at a light wavelength of 215 nm
(Fig. 4A) clearly showed a large major peak corresponding
to a molecular size of 57 kDa, a smaller one corresponding
to 110 kDa, while the 80 and 67 kDa peaks appeared as
a shoulder between the other two peaks.
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Fig. 2. Isomerization of DLPs and OvCNPs. RP-HPLC traces of incubation mixtures containing the speciﬁed peptides sampled at various
incubation times at 37 C. The peptides used were: (A) DLP-4; (B) DLP-2; (C) DLP-4A; (D) DLP-2A; (E) OvCNPa and; (F) OvCNPb. To decrease
protease degradation of OvCNPs during long incubation times, the sample in (E) was incubated at 37 C for the ﬁrst 5 h and at 32 C thereafter.
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Fig. 3. Amastatin and methanol inhibition of the DLP isomerase. RP-
HPLC traces of an incubation mixture after 3 h at 37 C. All samples
contained the same amounts of DLP-2, >30 kDa fraction of venom
gland extract, and 40 mM EDTA.
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isomerase activities of the diﬀerent 1.5 mL fractions of a ve-
nom gland extract. As shown, no isomerase activity was ob-
served for fraction 1 which contained most of the 110-kDa
fraction. Maximum isomerase activity was located in fraction
3 (f3) from the Superdex 75 column. The fact that this fraction
contained most of the abundant 57 kDa component suggested
that the DLP isomerase has a size at or near 57 kDa. Lowerisomerase activity was measured in fractions 2 and 4, which
all contained proteins at or near 57 kDa, respectively; while
fractions 1, and 5 onwards were devoid of any activity. These
results imply that the active component has a size between 50–
80 kDa. The size was narrowed down even further by noting
that all active fractions contained the 57 kDa protein, and that
the 66 and 80 kDa proteins were most abundant in fraction 2
and were less abundant (if even present) in fraction 4. There-
fore, the DLP isomerase was concluded to have a size closer
to 57 than to 66 kDa.4. Discussion
We have shown here that platypus venom gland extracts
contain an isomerase(s) that interconverts the second residue
in DLP-4/-2 and OvCNPa/b between the L-form and D-form.
This platypus isomerase is the ﬁrst such enzyme to be discov-
ered in a mammal. Its presence opens up the possibility that
other D-amino-acid-containing peptides and their respective
isomerase(s) may be present in higher organisms, including hu-
mans. The functions of these D-amino-acid-containing pep-
tides in platypus venom are not clear since the true roles of
the DLPs and OvCNPs in venom action are yet to be estab-
lished. However, these unusual peptides are likely to be phys-
iologically important in the venom as the DLPs are the most
abundant polypeptides in the venom [3], while OvCNPs had
been shown to possess potent antihypertensive activity [7,8].
The venom isomerase from the funnel-web spider, Agelenop-
sis aperta, that acts on the third amino-acid residue from the
C-terminus was characterized approximately a decade ago
and was found to be similar in structure to serine proteases
[20,21]. More recently, Jilek and co-workers discovered an
isomerase of 52 kDa from frog skin that converts the L-ami-
no acid at position 2 of its substrate to the D-form [26]. It is
tempting to speculate that the isomerase in the platypus is
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Fig. 4. Size exclusion chromatography of the whole gland extract and
isomerase activities of fractionated samples. (A) Size exclusion chro-
matogram of 50 lL of gland extract using a Superdex 75 HR column
detected at a light wavelength of 215 nm. The largest peak which
corresponded to a protein with size 57 kDa by column calibration
was collected (fraction M) and was analyzed further by gel electro-
phoresis. (B) SDS–PAGE gel of MW standards, the whole extract, and
fraction M that shows protein bands with sizes of 57, 67, 80, and
110 kDa. (C) Size-exclusion chromatogram proﬁles of 50 lL fraction-
ated samples, f1 (——), f2 , f3 (  ), f4 (- - -), and f5 detected
at a light wavelength of 215 nm. The samples were obtained by
collecting 1.5 mL fractions during size-exclusion chromatography of
100 lL gland extract. The inset shows a histogram of isomerase
activity. (D,E) RP-HPLC traces of the incubation mixture containing
DLP-4 for each fraction after 1 h (D) and 26 h (E) of incubation at
37 C.
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be diﬀerent since many proteins and peptides discovered in the
platypus venom are unique [4,10]. We considered it likely thatthe platypus isomerase bears similarity of its active site with
some aminopeptidases since they both act on or near the N-
terminus of a peptide. This was investigated by studying the ef-
fects of a competitive inhibitor of aminopeptidases, amastatin,
on the DLP-2/DLP-4 conversion by a fractionated venom
gland extract. The results showed that amastatin was inhibi-
tory, although the presence of methanol reduced the rate of
conversion. Moreover, the experiments using the 12-residue
DLP analogues convincingly demonstrated that residues 8–
42 of DLP-2 or DLP-4 are not critical for the isomerase activ-
ity.
Eﬀorts are underway to purify the isomerase using comple-
mentary chromatographic techniques such as ion-exchange,
and RP-HPLC. Our results show that there are many protein-
aceous components in the extract with MW between 50 and
60 k and that the enzyme is only present in minute quantities;
this makes further characterization complicated. We are cur-
rently sequencing bands isolated from active fractions on the
SDS–PAGE gel and are constructing a cDNA library of the
platypus venom gland so that we can isolate and express puta-
tive isomerase genes and test their activities. Once isomerase
activity is demonstrated in these expressed proteins, we will
search for homologues in therian (marsupial and eutherian)
mammals. The platypus last shared a common ancestor with
humans over 210 million years ago, yet it is possible that this
enigmatic creature may reveal new insights into human biology
and medicine.
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